KBC Group Trims DexCom Stake by 30.9%

Institutional investor reduces position in medical device company

Apr. 18, 2026 at 8:00am

Got story updates? Submit your updates here. ›

An extreme close-up of complex, metallic medical machinery and sensors, conveying the advanced engineering and technology behind continuous glucose monitoring devices.An institutional investor's reduction in holdings of a leading medical device company reflects broader shifts in the healthcare technology market.San Diego Today

KBC Group NV, an institutional investor, has trimmed its stake in DexCom, Inc. (NASDAQ:DXCM) by 30.9% in the fourth quarter, according to a recent SEC filing. The company now owns 298,339 shares of the medical device company's stock, down from 431,839 shares previously.

Why it matters

This transaction provides insight into the investment strategy of KBC Group, a major institutional investor. The reduction in DexCom holdings could signal a shift in the firm's outlook on the medical device company or broader market conditions.

The details

According to the SEC filing, KBC Group sold 133,500 shares of DexCom stock in the fourth quarter. The institutional investor now owns approximately 0.08% of DexCom's outstanding shares, down from 0.12% previously. DexCom is a leading manufacturer of continuous glucose monitoring (CGM) systems for people with diabetes.

  • The transaction occurred in the fourth quarter of the reporting period.

The players

KBC Group NV

A major institutional investor that has reduced its stake in medical device company DexCom, Inc.

DexCom, Inc.

A medical device company that develops and manufactures continuous glucose monitoring systems for people with diabetes.

Got photos? Submit your photos here. ›

The takeaway

This transaction highlights the shifting investment landscape, as major institutional players reevaluate their positions in the medical technology sector. The reduction in KBC Group's DexCom holdings could signal broader market trends or a change in the firm's outlook on the company's prospects.